Abstract
Aspects of measurement of plasma protein-binding of drugs and the representation and interpretation of such data, together with the effect of altered binding on pharmacokinetics and the impact on therapeutic plasma drug concentration monitoring, are reviewed. In most instances, altered binding affects interpretation of plasma concentration data rather than causes a need for a change in the usual dosage regimen.